Coding of DNA samples and data in the pharmaceutical industry: Current practices and future directionsperspective of the I-PWG

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 537-545

  Franc, M A ^a   Cohen, N ^a   Warner, A W ^b   Shaw, P M ^c   Groenen, P ^b   Snapir, A ^d  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Merck Research Laboratories   (United States)

^d Orion Pharma R and D   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; CLINICAL RESEARCH; DNA CODING; DRUG INDUSTRY; ETHICS; GENETIC PRIVACY; MEDICAL PRACTICE; MOLECULAR GENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL;

CLINICAL CODING; CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DNA; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACOGENETICS; PRIVACY; SPECIMEN HANDLING;

EID: 79952994279     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.306     Document Type: Article

References (15)

1. Franc, M.A., Warner, A.W., Cohen, N., Shaw, P.M., Groenen, P. & Snapir, A. Current practices for DNa sample collection and storage in the pharmaceutical industry, And potential areas for harmonization. Clin. Pharmacol. Ther. 89, 546-553 (2011).
2. Harmon, A. Tribe wins fight over research on its DNa. New York Times, 22 april 2010.
3. International Conference on Harmonisation. ICH Guideline for Good Clinical practice E6(R1) http://www.Ich.Org/fileadmin/public-Web-Site/ iCH-products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.Pdf (1996).
4. Ricci, D.S. et al. Global requirements for DNa sample collections: results of a survey of 204 ethics committees in 40 countries. Clin. Pharmacol. Ther. 89, 554-561 (2011).
5. Warner, A.W. et al. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics Working Group. Clin. Pharmacol. Ther. 89, 529-536 (2011).
6. International Conference on Harmonisation. ICH Guideline for Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories E15 http://www.Ich.Org/fileadmin/public- Web-Site/iCH-products/Guidelines/Efficacy/E15/Step4/E15-Guideline.Pdf (2007).
7. Spear, B.B. et al. Terminology for sample collection in clinical genetic studies. Pharmacogenomics J. 1, 101-103 (2001).
8. Health insurance portability and accountability act (Hipaa) of 1996 (45CFR 164.514) http://www.Hhs.Gov/ocr/privacy/hipaa/administrative/ privacyrule/adminsimpregtext.Pdf .
9. Directive 95/46/EC of the European parliament and of the Council http://eurlex.Europa.Eu/LexUriServ/LexUriServ.Do?uri=CELEX:31995L0046:en:HTML (1995).
10. European Commission. Data protection Working party. Opinion 4/2007 on the concept of personal data http://ec.Europa.Eu/justice/policies/privacy/docs/ wpdocs/2007/wp136-en.Pdf (2007).
11. Beyond the HIPAA Privacy Rule (National academies press, Washington, DC, 2009).
12. Lin, Z., Owen, A.B. & Altman, R.B. Genetics. Genomic research and human subject privacy. Science 305, 183 (2004). (Pubitemid 38886715)
13. Sweeney, L. Weaving technology and policy together to maintain confidentiality. J. Law Med. Ethics 25, 98-110, 82 (1997). (Pubitemid 127448006)
14. Fed. Reg. 53181, 53226 (2002).
15. Office for Civil Rights. Workshop on the Hipaa privacy Rule's De-identification Standard. http://www.Hhs.Gov/ocr/privacy/hipaa/understanding/ coveredentities/De-identification/deidentificationworkshop2010.Html .